Latest Articles

Publication Date
All News Scientific
Endometriosis: ‘If I was believed 10 years ago, maybe it wouldn’t be this extensive’ - The Irish Times

Endometriosis: ‘If I was believed 10 years ago, maybe it wouldn’t be this extensive’ The Irish Times

Published: Dec. 4, 2024, 6:02 a.m.
Read Full Article
Why managing mould could be the secret to optimising your health - Women's Health

Why managing mould could be the secret to optimising your health Women's Health

Published: Dec. 4, 2024, 3:41 a.m.
Read Full Article
What is Visanne, the endometriosis drug just added to the PBS? - New Zealand Doctor Online

What is Visanne, the endometriosis drug just added to the PBS? New Zealand Doctor Online

Published: Dec. 4, 2024, 1:33 a.m.
Read Full Article
New research links depression to more painful periods - Fast Company

New research links depression to more painful periods Fast Company

Published: Dec. 3, 2024, 9:02 p.m.
Read Full Article
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn

Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn

Published: Dec. 3, 2024, 6:36 p.m.
Read Full Article
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive

Published: Dec. 3, 2024, 5:11 p.m.
Read Full Article
Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test | AWH Stock News - StockTitan

Aspira Women's Health Secures $2M ARPA-H Grant for AI-Powered Endometriosis Test | AWH Stock News StockTitan

Published: Dec. 3, 2024, 1 p.m.
Read Full Article
Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News - StockTitan

Karyopharm Delays Endometrial Cancer Program Update Amid FDA Discussions | KPTI Stock News StockTitan

Published: Dec. 3, 2024, noon
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!